Forte fields demand to liquidate from top shareholder who says latest asset came ‘out of thin air’news2022-05-25T15:02:22+00:00May 25th, 2022|FierceBiotech|
BridgeBio’s CEO on staying alive, ‘motherhood and apple pie’news2022-05-25T14:36:12+00:00May 25th, 2022|FierceBiotech|
With failed COVID shot still dragging on earnings, CureVac tries to turn page to next-gen mRNA technews2022-05-25T13:45:23+00:00May 25th, 2022|FierceBiotech|
Antios rocked as hepatitis B safety signal sparks clinical hold, termination of collaborationnews2022-05-25T11:43:58+00:00May 25th, 2022|FierceBiotech|
Insurer plans $4B investment blitz to add lab space outside of U.S. biotech hot spotsnews2022-05-25T08:22:52+00:00May 25th, 2022|FierceBiotech|
ASCO: I-Mab, Junshi’s cancer combo performs best as a first-line NSCLC treatment, with signals for CD73 as a biomarkernews2022-05-24T21:40:47+00:00May 24th, 2022|FierceBiotech|
ASCO: J&J’s multiple myeloma toolkit expands with bispecifics datanews2022-05-24T16:28:24+00:00May 24th, 2022|FierceBiotech|
CSL Behring gene therapy makes comeback after hold for FDA priority reviewnews2022-05-24T14:29:16+00:00May 24th, 2022|FierceBiotech|
Genocea closes up shop after failing to find a buyer, delists from Nasdaqnews2022-05-24T14:18:23+00:00May 24th, 2022|FierceBiotech|
Manufacturing concerns sideline INmune’s US Alzheimer’s trialnews2022-05-24T13:46:53+00:00May 24th, 2022|FierceBiotech|
